role glutathion s-transferas gstpi tumor develop previous suggest howev exact function enzym carcinogenesi remain unclear gstpi identifi modul cell signal interact inhibit c-jun n-termin kinas jnk kinas turn describ regul p53 stabil transcript activ studi possibl interact gstpi p53 cross gstpi-defici anim p53 -/- mice doubl knock anim viabl develop tumor month ag life span anim howev similar gstpi +/- /p53 -/- gstpi +/+ /p53 -/- mice heterozyg p53 live significantli longer p53 -/- anim develop tumor much later express gstpi significantli modifi life span anim contrast wild-type p53 background gstpi -/- mice develop tumor significantli higher frequenc heterozyg wild-type anim median tumor free life span week shorter addit p53 +/+ background on third gstpi -/- anim develop lung adenoma gstpi +/- gstpi +/+ present tumor gstpi express alter express tumorigenesi marker cox-2 ornithin decarboxylas respons phorbol ester furthermor gstpi-defici mous embryo fibroblast sensit -induc apoptosi p53 -/- cell independ gstpi statu sensit dna damag agent wild-type counterpart result suggest gstpi plai protect role develop spontan tumor
14q32 transloc 14q repres critic univers event multipl myeloma gain chromosom arm 11q +1q +9q +11q recent identifi frequent aberr diseas pathogenet signific remain unclear studi seri 108 patient us fluoresc situ hybrid dna probe map chromosom band 1q21 9q34 11q25 13q14 14q32 three subset tumor defin mm+/+ detect +9q +11q 43.5 case mm+/- +9q +11q 21.3 mm-/- neither +9q nor +11q 35.2 incid 14q significantli differ subgroup mm+/+ mm+/- mm-/- delet 13q 13q- significantli frequent mm+/+ mm+/- mm-/- respect nonrandom distribut chromosom aberr present seri tumor point novel 14q32 transloc-independ pathogenet pathwai plasma cell neoplasm
multipl myeloma malign plasma cell disord character complex karyotyp chromosom instabl cytogenet level chromosom instabl gener involv partial duplic whole-arm transloc jump transloc identifi g-band character instabl perform spectral karyotyp fluoresc situ hybrid probe satii/iii 1q12 bcl9 1q21 il6r 1q21 karyotyp patient known aberr eight patient segment duplic 1q12-21 adjac band occur nonhomolog chromosom five case first jump nonhomolog chromosom 1q12-21 segment duplic 1-3 time three case segment duplic occur first jump nonhomolog chromosom proxim adjac nonhomolog chromosom segment duplic prior jump insert locat case demonstr satii/iii dna sequenc associ duplic adjac distal chromosom segment transloc associ duplic jump/insert proxim nonhomolog chromosom segment design type instabl jump segment duplic
cdkn2a tumor-suppressor locu chromosom band 9p21 encod p16 ink4a neg regul cyclin-depend kinas p14 arf1 activ tp53 inactiv human cancer point mutat promot hypermethyl delet homozyg delet unusu preval locu differ human cancer present studi compar delet squamou cell carcinoma head neck scchn cell line t-cell acut lymphat leukemia t-all glioma bladder carcinoma tcc cell line scchn line show homozyg delet cdkn2a on displai promot hypermethyl gene silenc on frameshift delet exon delet end proxim repetit sequenc cluster flank locu breakpoint junction displai variabl microhomolog insert characterist dna repair nonhomolog end-join gener delet much smaller scchn tcc glioma t-all breakpoint consensu site recombin mediat rag recombin activ gene enzym structur junction consist mechan suggest differ mechan cdkn2a delet prevail differ human cancer aberr rag-mediat recombin respons t-all exuber dna repair nonhomolog end-join like prevail mechan scchn distinct mechan tcc glioma remain elucid
investig genet basi great heterogen observ clinic behavior multipl myeloma combin approach g-band interphas fluoresc situ hybrid fish multicolor fish m-fish emploi analyz sampl patient g-band reveal abnorm karyotyp case origin chromosom marker identifi revis m-fish combin metaphas karyotyp data interphas fish find us immunoglobulin heavi-chain igh igh/cyclin gene ccnd1 d13s319 probe reveal chromosom abnorm evalu patient mark inter- intratumor cytogenet heterogen investig sampl cytogenet unrel clone detect case mostli evalu diagnosi wherea cytogenet clonal evolut manifest relat clone case associ diseas progress among 14q32 rearrang present case least three cytogenet subset identifi on usual 13q14 delet anoth igh chang 13q14 delet hypodiploid modal chromosom number third chang 14q32 abnorm chromosom correl found cytogenet clinicopatholog characterist provid support concept gener genom featur conjunct specif chromosom rearrang defin malign phenotyp variou subset
us combin high throughput function genom computer databas mine express analys discov novel human tumor suppressor gene tsg genom-wide high throughput cdna phenotyp screen establish identifi gene induc apoptosi reduc cell viabil tsg express normal tissu frequent act reduct growth transform cell induc apoptosi agreement serv platform valid pro-apoptot hit includ gene tumor suppress activ known kangai1 cd81 antigen addit gene claim put tsg associ tumor inhibitori activ prostat differenti factor hra-like suppressor dph2l1-like metastasi inhibitor kiss1 confirm propos tsg-like phenotyp function defin growth inhibitori pro-apoptot function cancer cell final novel gene identifi neither associ cell growth nor apoptosi previous describ subset gene show characterist tsg becaus reduc growth induc apoptosi tumor cell show reduc express tumor normal tissu iii locat chromosom loh- loci cancer-associ delet describ pro-apoptot phenotyp differenti express gene normal malign tissu make promis target candid diagnosi therapi variou tumor
background neuroblastoma deriv cell neural crest origin express transcript factor human achaet-scute homolog hash1 aim studi select kill neuroblastoma cell express suicid gene coli purin nucleosid phosphorylas pnp under control mash1 promot murin homolog hash1 procedur coli pnp gene regul mash1 promot clone express vector transfect neuroblastoma non-neuroblastoma cell line addit prodrug m2-fluoroadenin 9-beta-d-arabinofuranosid f-araa cell-specif toxic examin optim cell specif activ differ size mash1 promot analyz neuroblastoma cell line compar activ non-neuroblastoma cell result estim percentag cmv enhanc-promot activ significantli higher neuroblastoma cell rang shortest most activ promot measur non-neuroblastoma cell yield 1-6 cmv promot activ shortest mash1 promot combin coli pnp gene cytotox neuroblastoma cell low cell death non-neuroblastoma cell line rel cytotox e.coli pnp gene regul strong non-specif cmv enhanc-promot conclus show here mash1 promot regul pnp gene confer cell-type select toxic neuroblastoma cell line result indic feasibl us mash1 promot regul e.coli pnp express gene-direct enzym prodrug therapi gdept neuroblastoma
downregul mhc class express widespread phenomenon us tumor cell escap antitumor t-cell-mediat immun respons alter plai role clinic cours diseas aim studi investig molecular mechan underli absenc hla-class molecul express bladder cancer cell microdissect tumor tissu character real-time quantit pcr express hla-abc beta2-microglobulin member antigen process machineri apm hla class molecul lmp2 lmp7 tap1 tap2 tapasin result show irrevers hla loss mutat beta2-microglobulin gene caus low hla class express bladder cancer contrast observ coordin transcript downregul hla-abc beta2-microglobulin apm gene microdissect tumor tissu deriv bladder carcinoma mechan repres major factor downregul hla class express subsequ direct recognit cancer cell cytolyt lymphocyt becaus regulatori mechan frequent revers ifn-gamma treatment conclud hla class express major consider immunotherapeut purpos patient bladder cancer
sever oncogen isol nih/3t3 transform assai i.e dbl db lbc lfc lsc net ost tim contain dbl homolog pleckstrin-homolog domain act gef guanin nucleotid exchang factor rho-like gtpase search gene oncogen potenti dna monocyt leukaemia cell line u937 identifi amino-termin truncat form gef-h1 gene encod gef rhoa data support idea systemat search mutat delet gef human cancer promis
hin-1 high normal-1 put cytokin growth inhibitori activ downregul aberr methyl breast cancer studi hin-1 methyl statu type adult pediatr malign cell line examin express hin-1 mrna cell line promot methyl statu cell line 800 primari tumor repres tumor type us methyl specif pcr promot methyl observ breast cancer nonsmal cell lung cancer nsclc small cell lung cancer sclc malign mesothelioma cell line methyl complet correl loss express express neg cell line restor hin-1 express treatment 5-aza-2'-deoxycytidin promot methyl hin-1 found retinoblastoma wilm' tumor rhabdomyosarcoma breast cancer prostat cancer mm nsclc lymphoma methyl frequenc colorect cancer cervic cancer bronchial carcinoid sclc neuroblastoma osteosarcoma leukemia medulloblastoma bladder cancer lower 4-21 hepatoblastoma lack methyl hin-1 methyl rare detect nonmalign tissu 165 aberr methyl hin-1 loss express common event contribut pathogenesi type human malign
studi 279 tumour salivari gland conduct analys whether assess dna ploidi flow cytometri assist histopatholog discrimin benign malign type tumour group benign tumour includ 164 pleomorph adenoma warthin's tumour basal cell adenoma lipoma well differ tumour 229 benign tumour diploid malign tumour consist adenoid cystic adenoma mucoepidermoid carcinoma acin cell carcinoma carcinoma pleomorph adenoma well malign belong differ tumour entiti twelv malign salivari gland tumour aneuploid signific relationship dna ploidi statu histopatholog grade lymph node metastasi local recurr develop respect three case initi taken pleomorph adenoma routin histolog examin aneuploid cell popul expos dna flow cytometr analysi gave rise closer inspect suspect lesion examin consecut slide actual reveal small assembl carcinoma cell requir final diagnosi non-invas carcinoma pleomorph adenoma most obviou valu dna flow cytometri salivari gland tumour contribut assist histopatholog identifi potenti malign lesion
soft tissu sarcoma stss aris abdomin caviti constitut group aggress tumour typic larg size high recurr rate affect patient distinct genet etiolog describ genet background tumour group well characteris here assess gross chromosom alter seri tumour obtain patient cgh alter found tumour patient most frequent loss 13q21 gain 17p furthermor mutat c-kit exon demonstr five tumour four patient two myxoid liposarcoma exhibit transloc q13 p11 pattern chromosom alter detect genet progress event clearli evid tumour taken togeth analysi subsequ relaps same patient common cgh alter +12q13 suggest rel earli event genet progress similar q13 p11 c-kit mutat moreov -1p21-22 -13q21 -14q -xp22 +9q34 +17p +17q +20q13 repres rel later event most consist alter loss 13q found target 13q14-21 13q34 region determin cgh southern blot analys loss 13q identifi independ +12q13 c-kit mutat patient's sex observ common subtyp st suggest gener late event genet progress find provid start point dissect target gene involv develop stss abdomin caviti
nasopharyng carcinoma npc distinct geograph diseas high incid southeast asia previou cgh studi locat multipl region chromosom gain loss npc elucid region gain amplif high-resolut arrai compar genom hybrid arrai cgh appli character common amplicon npc cell line xenograft consist previou cgh find frequent gain chromosom 12q 20q detect high incid gain identifi chromosom 12q find confirm fish analysi us bac clone 3q26-28 bac clone 12q13 smallest region gain 12q defin five npc cell line chromosom 3q26.33 rp11-510k16 12q13.2-q13.3 rp11-183h16 show highest amplif frequenc fish analysi 100 66.7 respect pik3ca candid oncogen locat 3q26.32 adjac amplicon investig real-time quantit revers transcriptas-polymeras chain reaction rt-pcr overexpress gene found npc cell line xenograft find impli pik3ca put oncogen involv tumorigenesi npc
prostat apoptosi respons-4 par-4 pro-apoptot protein origin identifi gene product upregul prostat tumor cell undergo apoptosi down-regul par-4 link sever cancer par-4 plai crucial role neuron apoptosi investig express par-4 tumor cell line deriv repres tumor type cn includ primit neuroectoderm tumor pnet medulloblastoma neuroblastoma glioma human rat murin origin show par-4 frequent down-regul transcription post-transcription cn tumor cell line moreov demonstr ectop express par-4 suffici directli induc apoptosi cn tumor cell contrast cancer cell replenish par-4 level sensit cell apoptot stimuli induct apoptosi par-4 neural tumor cell line independ endogen bcl-2 level pkczeta activ propos par-4 exert pro-apoptot function down-modul bcl2 express inhibit pkczeta co-express par-4 domin-neg mutant fadd result slight reduct apoptosi tumor cell line indic par-4 partial induc apoptosi via fa death pathwai furthermor data suggest pro-apoptot function par-4 involv yet unidentifi apoptot pathwai cn tumor cell line par-4 suffici induc apoptosi non-tumor cell reintroduct par-4 primari cn tumor reactiv pathwai par-4-mediat apoptosi repres promis target anti-tumor therapi
sialic acid-contain glycosphingolipid gangliosid express high level nerv tissu variou tumor cell number studi role gangliosid regul cell prolifer perform mechan regul well understood establish pc12 transfect cell over-express gm1 us clone beta1 3-galactosyltransferas 2.4.1.62 cdna analyz growth growth signal epiderm growth factor egf over-express gm1 enhanc cell prolifer egf under low serum cultur condit phosphoryl level egf receptor downstream map kinas egf stimul sustain min transfect cell contrast swiss3t3 cell previous report growth suppress gm1 over-express due dramat chang intracellular local pdgf receptor pc12 transfect cell beta1 3-galactosyltransferas cdna show clear chang intracellular local egf receptor microdomain/raft fraction experi compar vector control cell result suggest effect gm1 express natur microdomain growth signal depend cell type receptor analyz
loss heterozygos loh analysi sensit method detect delet specif chromosom region consid harbor put tumor suppressor gene tsg previou allelotyp analys variou human cancer suggest presenc least on tsg chromosom 19p13 region function analysi brg1 member swi/snf complex protein locat 19p13.2 suggest candid tsg differ type human cancer examin loh 19p13 region oral cancer us six microsatellit marker found allel delet sampl microsatellit marker brg1 locu show highest loh tumor sampl clarifi role brg1 gene oral carcinogenesi check mutat statu tumor sampl mutat brg1 gene detect oral cancer examin mrna express level quantit rt-pcr analysi surprisingli demonstr increas express brg1 mrna primari tumor compar match normal sampl function brg1 brm anoth member swi/snf highli homolog brg1 interrel examin brm mrna express same sampl most sampl express brg1 brm chang same direct consist report data human cancer cell line import find express altern frame splice form brg1 includ exon select decreas lost most tumor sampl uniqu amino-acid sequenc brg1 protein show high homolog heterogen nuclear ribonucleoprotein affect function level brg1 through modif post-transcript control find suggest genet epigenet alter brg1 role oral cancer develop
cytogenet analysi perform primari tumor pair recurr metastat lesion patient head neck squamou cell carcinoma hnscc order identifi chromosom aberr associ tumor initi progress abnorm karyotyp found patient distinct karyotyp similar shown inform pair individu patient degre karyotyp complex similar primari pair recurr metastat lesion sampl clonal chromosom aberr displai complex karyotyp multipl numer unbalanc structur rearrang result extens genom imbal pathwai clonal evolut trace few patient support notion aberr imbal particularli partial entir loss homogen stain region commonli map 11q13 earli genet event initi hnscc
us compar genom hybrid investig chang dna copi number nonfunct endocrin pancreat tumor total number region dna imbal per tumor show variat case case high genet heterogen observ chromosom anomali detect case evalu overal gain predomin loss ratio 3.9 gain/15 loss mean total number region displai imbal increas 1.25 per tumor benign tumor 5.25 malign tumor statist signific reach 0.074
studi consist 100 patient male femal suffer bladder cancer match control maximum number patient studi ag group 61-70 year preval genet polymorph cyp2d6 gstm1 gstt1 gene investig find associ risk bladder cancer associ heterozyg hem genotyp cyp2d6 gene risk bladder cancer [odd ratio 1.00 confid interv 0.46-2.16] 1.5-fold poor metabol genotyp stratifi accord differ grade bladder cancer signific associ found 3.54 0.89-13.98 grade 3.3 0.12-20.6 grade iii 1.67 0.15-18.45 grade stratifi relat smoke statu signific associ diseas found heavi smoker 2.13 0.71-6.43 subject null genotyp gstm1 slightli signific associ bladder cancer risk risk increas 2-fold gstt1 null genotyp smoke statu reveal impact preval bladder cancer individu gstm1 gstt1 null genotyp result indic 3-fold increas risk develop cancer presenc on copi variant cyp2d6 hem allel null gstt1
death induct walker 256 tumor cachexia non-tumor-infiltr lymphocyt investig lymphocyt cachect tumor-bear rat present higher proport cell ruptur membran indic necrot cell death cachexia induc walker 256 tumor increas 3.6-fold percentag cell fragment dna suggest apoptot cell death mitochondria involv examin analysi mitochondria transmembran potenti us rhodamin 123 lymphocyt cachect tumor-bear rat present pronounc depolar mitochondri transmembran potenti comparison cell control group express import proapoptot bcl-xs bax p53 caspas-3 antiapoptot gene bcl-2 bcl-xl alter tumor cachexia result suggest immunosuppress induc walker 256 tumor cachexia least part result lymphocyt death evid found involv mitochondria import proapoptot gene process lymphocyt death walker 256 tumor cachexia
gastrointestin stromal tumor gist specif rare subset human gastrointestin tract tumor most gist show gain-of-function mutat kit mainli exon maintain read frame report data 43-year-old japanes man recurr duoden gist frameshift mutat kit exon togeth in-frame delet kit exon detect genom dna sequenc delet base pair kit exon preserv read frame identifi both primari recurr tumor wherea delet on nucleotid codon 642 kit exon chang read frame induc novel stop codon amino acid 644 found recurr tumor predict protein result latter lack part kinas domain best knowledg first document gist frameshift mutat kit
chromosom transloc involv immunoglobulin heavi chain igh locu variou partner loci frequent associ multipl myeloma investig express profil fgfr3/mmset ccnd1 ccnd3 maf mafb gene involv p16.3 q32 q13 q32 p21 q32 q32 q23 q32 q12 respect purifi plasma cell popul mm six plasma cell leukemia pcl dna microarrai analysi compar result presenc transloc assess dual-color fish rt-pcr found mm mm pcl mm pcl pcl case transloc associ spike express target gene furthermor gene express profil enabl identif put transloc caus dysregul ccnd1 pcl mafb pcl appar involv immunoglobulin loci notabl transloc mutual exclus markedli increas mmset express found show associ fgfr3 mmset signal unidentifi chromosom data suggest import us combin molecular cytogenet gene express approach detect genet aberr
norcantharidin nctd demethyl analogu cantharidin us treat human cancer china 1984 recent found capabl induc apoptosi human colon carcinoma hepatoma glioblastoma cell wai elus mechan studi demonstr nctd induc apoptosi human oral cancer cell line sa p53 wild-type phenotyp ca9-22 p53 mutant evidenc nuclear condens tunel label dna fragment cleavag parp apoptosi induc nctd both dose- time-depend found nctd induc fa fasl impli activ apoptosi pathwai data show nctd caus accumul cytosol cytochrom activ caspas-9 suggest apoptosi occur via mitochondria mediat pathwai nctd enhanc express bax sa cell consist p53 statu moreov show nctd downregul express bcl-2 ca9-22 bcl-xl sa result suggest nctd-induc apoptosi oral cancer cell mediat increas ratio proapoptot antiapoptot protein oral cancer cell mutant p53 elev bcl-xl level show resist multipl chemotherapeut agent nctd overcom chemoresist cell provid potenti avenu treatment
head neck cancer hnscc on most distress human cancer caus pain affect basic surviv function breath swallow mortal rate chang despit recent advanc radiotherapi surgic treatment compar express 000 uniqu gene case match hnscc normal oral mucosa 260 gene show statist signific differ express normal tumor tissu mrna level three top rank top select analysi immunohistochemistri paraffin section along tumor suppressor gene p16 p53 total patient includ 4-year clinic data avail us univari multivari surviv analysi identifi sparc/osteonectin power independ prognost marker short diseas-free interv dfi &lt 0.002 poor overal surviv 0.018 hnscc patient combin ecm protein found analysi pai-1 upa associ dfi becam signific &lt 0.001 studi repres first instanc sparc independ prognost marker hnscc
genet polymorph affect express activ correspond enzym influenc risk acquir gene mutat variou cancer studi 327 bladder cancer patient regard function relat polymorph gstm1 gstt1 gstp1 nat2 analys p53 mutat statu tumour fifti p53 mutat transvers transit detect patient p53 mutat frequenc significantli higher higher-grade tumour low-grade tumour 2.09 1.44-3.02 adjust ag sex signific associ found tumour stage ti t2+ presenc gstp1 val allel adjust 2.00 1.14-3.52 overal signific differ frequenc p53 mutat among patient differ genotyp among patient p53 mutat transvers significantli frequent gstm1-neg compar gstm1-posit individu 5.18 1.07-25.02 adjust ag sex tumour stage on except tumour most common type transvers c-c occur gstm1-neg patient among smoker transvers transit found among carrier gstp1 variant allel sampl carri least variant gstp1 allel transit cpg site wild-type sampl adjust 4.61 0.82-26.04 signific associ found nat2 gene result suggest impair glutathion conjug affect mutat spectrum critic target gene
screen popul earli detect asymptomat malign potenti malign intuit attract strategi control reduc burden oral cancer societi subsequ prevent therapeut measur howev substanti prospect random control trial rct markedli improv patient outcom reconcil usag 'scarc' healthcar resourc strateg object like achiev adopt preced establish cardiolog prevent emphas treatment occult lesion exampl screen identif individu high oral carcinogen risk will offer potenti educ opportun chang behavior optim implement contemporari prevent therapeut measur non-compliant individu imper substanti effect screen assai test prospect rct ignor safeguard public potenti fals-neg fals-posit diagnos
background neuroblastoma cytogenet character number non-random event howev knowledg limit concern time occurr inter-action event method karyotyp pattern obtain studi group tumor analyz convent cytogenet combin fish instanc sky result chromosom involv numer structur aberr least on tumor posit correl occurr mycn del del 17q aberr involv chromosom del consid earli event wherea involv chromosom late event conclus studi suggest karyotyp pattern character complex aberr group earli late karyotyp event other gain 17q variabl
background optim time attempt remov primari tumor region diseas patient high-risk neuroblastoma uncertain purpos studi evalu resect primari tumor region diseas determin radiograph children high-risk neuroblastoma neoadjuv chemotherapi procedur patient enrol institut high-risk neuroblastoma protocol evalu prospect scan mri determin resect primari tumor region diseas diagnosi two cycl experiment therapi standard induct therapi tumor consid unresect signific involv major vascular structur contigu organ like requir nephrectomi remov entir tumor result twenti-four patient refer prior surgeri treatment high-risk neuroblastoma seven patient felt resect diagnosi addit patient becom resect initi experiment therapi overal patient felt resect complet initi therapi four addit patient remain eight consid resect complet standard induct therapi conclus base data conclud complet resect primari tumor region diseas children high-risk neuroblastoma perform initi phase therapi major patient earlier tumor remov decreas chanc subsequ develop chemotherapi-resist diseas recommend surgic resect soon locoregion diseas appear resect
previou investig reveal bladder cancer cell gener resist fa-mediat apoptosi convent fa agonist howev abil cell line undergo fa-mediat apoptosi underappreci result investig vitro efficaci fa ligand gene therapi bladder cancer three human bladder cancer line t24 j82 5637 treat convent fa agonist ch-11 monoclon antibodi fa receptor cell treat replic-defici adenoviru contain modifi murin fa ligand gene fuse green fluoresc protein gfp adgfpfasl viru contain gfp gene alon us control viral toxic adgfp cell death quantifi us tetrazolium-base mt assai cell evalu western blot evalu poli adp-ribos polymeras caspas caspas cleavag flow cytometri determin presenc coxsacki/adenoviru receptor car studi confirm bladder cancer resist cell death anti-fa monoclon antibodi ch-11 resist overcom adgfpfasl multipl infect moi 1000 achiev cell death cell line furthermor greater cell death evid 5637 cell treat low-dose adgfpfasl moi 5637 cell express significantli higher level surfac car j82 t24 cell p&lt .05 adgfpfasl cytotox bladder cancer cell consid fa resist support vivo potenti enhanc sensit adgfpfasl part due increas cell surfac car level
report describ vector system specif deliv transgen product tumor intraven i.v administr escherichia coli cytosin deaminas gene place e3b region tumor-select replic-compet adenoviru onyx-411 under control endogen viral late gene regulatori element express directli coupl tumor-select replic viral vector vitro express effici variou human cancer cell line test cultur normal human cell includ human hepatocyt i.v administr nude mice carri human tumor xenograft robust activ detect tumor liver normal tissu level activ tumor increas progress i.v viru administr correl close viru replic vivo subsequ administr 5-fluorocytosin 5-fc demonstr trend improv antitumor efficaci virus mous xenograft model presum due intratumor convers 5-fc chemotherapeut drug 5-fluorouracil show combin highli select oncolyt viru onyx-411 strateg us viral e3b region transgen insert provid power platform allow tumor-specif persist robust transgen express i.v administr technolog provid opportun enhanc greatli both safeti efficaci cancer gene therapi
cytotox platinum compound thought determin primarili dna adduct cisplatin oxaliplatin structur distinct form same type adduct same site dna howev dna adduct differenti recogn number cellular protein exampl mismatch repair protein damag-recognit protein bind cisplatin-gg adduct higher affin oxaliplatin-gg adduct differenti recognit cisplatin- oxaliplatin-gg adduct thought contribut differ cytotox tumor rang cisplatin oxaliplatin detail kinet analysi insert extens step dntp incorpor vicin adduct show both dna polymeras beta pol beta dna polymeras eta pol eta catalyz transles synthesi past oxaliplatin-gg adduct greater effici past cisplatin-gg adduct case pol eta effici fidel transles synthesi vitro similar previous observ cyclobutan dimer suggest pol eta like involv error-free bypass adduct vivo confirm cisplatin compar cisplatin-induc mutat frequenc human fibroblast cell line pol eta greater effici bypass oxaliplatin-gg adduct pol eta explain lower mutagen oxaliplatin compar cisplatin abil cellular protein discrimin cisplatin oxaliplatin adduct suggest exist signific conform differ adduct yet crystal structur cisplatin- oxaliplatin-gg adduct similar recent solv solut structur oxaliplatin-gg adduct shown significantli differ previous publish solut structur cisplatin-gg adduct furthermor observ differ conform provid logic explan differenti recognit cisplatin oxaliplatin adduct mismatch repair damag-recognit protein
purpos review multipl endocrin neoplasia men type rare hereditari cancer syndrom express varieti mainli endocrin neoplasia improv understand molecular clinic genet associ lesion will like enhanc diagnosi treatment patient diseas recent find men1 gene caus men1 tumor suppressor gene seem act regul transcript machineri novel genet diagnost modal tend identifi neoplast lesion earlier stage potenti improv outcom qualiti life improv understand genotyp-phenotyp correl men2 caus mutat ret oncogen enabl individu treatment patient summari recent advanc molecular patholog diagnosi manag patient men1 men2 review
purpos review pheochromocytoma rare clinic import tumor chromaffin cell advanc understand genet alter caus hereditari form increas sensit biochem assai allow earli identif high risk individu famili surgic intervent remain treatment choic patient pheochromocytoma articl review recent develop diagnosi treatment pathophysiolog pheochromocytoma object develop guidelin identif manag diseas emphas current diagnost surgic approach discuss potenti futur develop field summari advanc molecular basi pheochromocytoma introduc diagnost modal refin imag techniqu improv rate detect metastat diseas innov surgic techniqu trial adren spare surgeri find nich surgic armamentarium
purpos review molecular genet alter character develop human cancer recent advanc molecular genet technolog success human genom project empow investig tool dissect cancer genom discoveri cancer-associ gene purpos review highlight emerg molecular genet methodolog summar principl applic potenti technic challeng critic issu sampl prepar strategi combin differ molecular techniqu facilit identif novel cancer-associ gene will discuss recent find digit karyotyp arrai-base techniqu includ arrai compar genom hybrid represent oligonucleotid microarrai analysi recent develop studi genom landscap human cancer innov provid tool quantit measur dna copi number chang cancer map chang directli onto human genom digit karyotyp base count sequenc tag distribut human genom provid digit readout precis outlin amplifi delet chromosom region arrai-base technolog hand compar content cancer refer genom follow local amplifi delet signal chromosom region us arrai hybrid techniqu addit high-throughput mutat analysi platform avail larg-scale mutat analysi us autom capillari sequenc devic sophist bioinformat tool number exampl demonstr promis molecular genet approach identifi sever potenti oncogen tumor suppressor summari compar convent cytogenet method digit karyotyp arrai compar genom hybrid represent oligonucleotid microarrai analysi provid unpreced map resolut allow precis local amplifi delet chromosom region technolog combin gene express profil high-throughput mutat analysi facilit search cancer-associ gene expect appli technolog will lead discoveri host novel oncogen tumor suppressor will signific impact understand tumorigenesi clinic manag cancer patient
purpos review signific insight gain complex biolog mechan cancer via combin comput experiment system biologi approach review highlight major system biologi effort appli cancer past year recent find two main approach comput system biologi discuss mechanist dynam simul inferenti data mine signific develop occur both area exampl mechanist simul egfr pathwai promot understand cancer bayesian infer approach allow reconstruct regulatori network addit articl report advanc experiment system biologi determin protein-protein interact quantifi protein express gener necessari data comput model inferenti data mine emerg approach will improv abil bridg gap vitro system vivo human biologi technolog pave wai includ vitro model better reflect vivo tumor microfabr devic human physiolog improv anim model summari import challeng face field better translat vitro discoveri clinic comput system biologi approach us omic data predict biologi along novel experiment system better repres human vivo biologi will prove us bridg gap still earli potenti applic system biologi futur evolut field will significantli affect understand cancer diseas mechan abil devis effect therapeut
purpos review transform growth factor beta type tgf-beta ubiquit cytokin well known abil inhibit epitheli cell prolifer somat mutat abrog tgf-beta signal transduct pathwai found gastrointestin cancer confirm import tumor suppressor contrast nongastrointestin epitheli malign lack somat alter yet cancer still acquir resist growth-inhibitori effect tgf-beta instanc resist part signal switch wherebi tgf-beta lose growth inhibitori effect us epitheli cell growth-promot fashion mechan underli chang phenotyp growth respons tgf-beta elucid review focus recent advanc understand dual natur tgf-beta pathwai relat human carcinogenesi recent find elucid molecular basi enabl epitheli cell chang growth-suppress growth-stimulatori phenotyp tgf-beta exposur area activ research besid enhanc cancer cell growth tgf-beta thought promot malign cell's abil metastas mediat chang cytoskelet architectur known epitheli-to-mesenchym transit process enabl cancer cell invad spread distal site strong evid emerg suggest abil cell us tgf-beta growth-promot/invas cytokin result number differ cellular nuclear factor includ absenc disrupt cyclin-depend kinas inhibitor imbal cell cycl regul kei element dictat cell's respons tgf-beta growth-inhibitori versu growth-stimulatori explain dual natur tgf-beta signal summari current studi shed light mechan allow nongastrointestin epitheli cancer evad growth inhibitori effect tgf-beta simultan us cytokin growth advantag dissect phenotyp switch tumor develop import gene protein pathwai involv tgf-beta signal continu discov knowledg premalign cell tumor cell respond growth promot effect tgf-beta gene regul process will aid develop novel therapeut treatment strategi
most microarrai experi signific fraction differenti express mrna identifi correspond express sequenc tag est gener discard analys us care bioinformat analys character est found highli overexpress seri pancreat adenocarcinoma cdna prepar non-neoplast sampl normal pancrea 20] normal colon 10] normal duoden mucos 30] pancreat cancer resect cancer 50] cancer cell line 14] hybrid complet affymetrix human genom u133 genechip set arrai u133a simultan analysi 000 fragment correspond 000 known gene 000 est geneexpress softwar system fold chang analysi tool us est identifi express level least 3-fold greater pancreat cancer compar normal tissu search human genom sequenc compar genom analysi human mous genom carri us basic local align search tool blast blastn blastx identifi protein code gene correspond est subsequ order pick most relev candid gene detail analysi look domain/motif open read frame us smart pfam program abl definit map est known novel gene est local close proxim gene human genom unabl establish est inde deriv gene differenti express subset gene confirm protein level immunohistochem label tissu microarrai inhibin beta [inhba] cd29 transcript level rt-pcr inhba akap12 elk3 foxq1 eif5a2 efna5 conclud bioinformat tool us character differenti overexpress est est repres diagnost therapeut us target miss us data sole current annot databas
inappropri activ transcript factor common event cancer transcript factor contribut malign phenotyp regul gene involv cellular prolifer surviv differenti angiogenesi invas import goal remain identifi target oncogen transcript factor execut chang stat protein among best-studi transcript factor involv oncogenesi both vivo vitro repres ideal model understand transcript factor caus cancer through coordin chang gene express recent studi emploi microarrai-base express analysi comprehens identifi stat target gene analysi target provid insight mechan neoplast transform shed light strategi target therapi
hypermethyl tumor suppressor gene caus aberr activ dna methyltransferas import mechan contribut cancer reaction mechan dna methyltransferas includ format coval intermedi enzym target base basi success sever anti-cancer drug target dna methyl includ 5-fluoro-2'-deoxycytidin 5-aza-2'-deoxycytidin decitabin 2-h pyrimidinon-1-beta-d 2'-deoxyribosid zebularin review provid insight chemistri dna methyl involv perform drug target
small interf rna current most wide us nucleic acid-base sequenc-specif gene silenc molecul molecul mediat rna interfer--a natur post-transcript gene-silenc pathwai given high reliabl higher effici small interf rna-mediat rna interfer compar earlier revers genet technolog prefer techniqu function genom furthermor exquisit specif except gene-silenc potenc small interf rna result intens research relat potenti target-specif therapeut applic molecul review will discuss mechan rna interfer applic pathwai molecular biologi includ function genom will overview articl will outlin vivo potenti clinic applic small interf rna molecul
thymidyl synthas inhibitor raltitrex rtx 5-fluorouracil fura shown promis anti-tumor activ preclin clinic set treatment colorect cancer effect two agent reason well-character cell line knowledg mode action vivo limit here util apc min/+ mous anim model intestin tumorigenesi studi effect rtx treatment alon combin fura rather surprisingli rtx monotherapi result dose depend 4-10-fold increas tumor number major adenoma 74-95 rather small i.e diamet exhibit loss heterozygos apc locu suggest increas mutat event lead tumor develop rtx augment brdu-label crypt epitheli cell retard movement cell along crypt-villu axi co-administr fura rtx result signific reduct tumor number compar mice treat rtx fura alon &lt 0.0001 addit fura abrog rtx-mediat increas brdu label result show rtx increas tumor burden apc min/+ mous yet enhanc anti-tumor effect fura first illustr vivo synergi rtx fura genet predispos anim model possibl mechan underli current observ discuss
tumor metastasi-the spread primari tumor cell distal organ major caus death cancer patient metastat process consist four distinct step invas intravas extravas metastat growth primari tumor cell need acquir differ genet characterist accomplish step main player metastat process remain howev larg unknown recent report cell robert weinberg's group yang cell 2004 117 927-39 add transcript factor twist list metastati regul suppress twist express tumor cell inhibit metastat potenti wherea overexpress induc epitheli-mesenchym transit emt epitheli cell studi provid direct evid emt essenti process metastasi appropri stimul investig emt laboratori
apoptosi best-character form program cell death pcd fundament import tissu homeostasi mammalian system two major pathwai involv initi apoptosi extrins death receptor pathwai intrins mitochondri pathwai pathwai act independ initi death machineri cellular system cell type includ numer tumor cell delic coordin cross talk extrins intrins pathwai lead activ execution caspas cascad addition appear fine balanc caspas-mediat arm death receptor signal engag mitochondria caspas-independ arm promot vacuol prolifer cell here review current knowledg layer complex pose interact death receptor-induc pathwai influenc mitochondria regul cellular life death decis
endostatin describ anti-angiogen factor endostatin look wai anti-angiogen treatment cancer unfortun object respons clinic trial us endostatin compar two differ endotheli cell type human umbil vein endotheli cell huvec endotheli cell deriv differenti embryon stem cell eesc test view endostatin induc prolifer apoptosi migrat endostatin bind both endotheli cell type shown opposit respons endostatin observ paramet depend us concentr quantiti huvec cell slightli reduc +/- treat ng/ml endostatin wherea eesc's show signific increas 142 +/- under same condit 0.01 observ endostatin abl evok non-uniform respons prolifer cell mount migrat endotheli cell differ endostatin bind characterist lead assumpt endostatin effect strongli depend endotheli cell type furthermor cell biolog respons lower concentr angiogen eesc give evid angiogen modulatori rather predict anti-angiogen role endostatin
object classic histolog grade molecular genet analysi epitheli hyperplast laryng lesion ehll correl attempt elucid classic marker reflect best gradual progress laryng premalign lesion determin increas number molecular genet aberr method thirti-two ehll group accord four grade nuclear atypia four degre epitheli matur three group overal suprabas mitot activ overal suprabas prolif activ measur mib-1 immunostain stage accord four level allel imbal determin pcr us microsatellit loci nine chromosom arm result six classic criteria progress mitot indic correl allel alter remark varieti microsatellit marker especi chromosom 17p conclus us number allel alter standard assess preliminari studi give first evid certain morpholog criteria reflect differ gradual progress premalign laryng lesion mitot index most promis marker studi long-term follow-up requir prove predict valu criteria daili practic
object extracellular nucleotid nucleosid induc prolifer set human glioma cell line studi investig signal transduct pathwai involv atp adenosin-mediat prolifer u138-mg human glioma cell method cell prolifer access through h]thymidin incorpor cell count flow cytometri protein phosphoryl detect through western blot result atp adenosin 100 microm induc extracellular signal-regul protein kinas erk akt gsk3beta phosphoryl increas h]thymidin incorpor induc atp adenosin decreas cell incub 294002 +/-90 109203x +/-76 098059 +/-63 increas cell number atp adenosin 48-hour treatment cell atp adenosin plu 109203x +/-66 294002 +/-83 percentag cell phase decreas cell treat 294002 plu atp compar atp- treat cell conclus stimul purinerg receptor u138-mg cell lead cell prolifer mediat pi3k/akt erk pkc signal clinic import pharmacolog intervent glioma associ purinerg receptor antagonist signal transduct pathwai blocker
background gp make difficult screen diagnost decis regard genet test differ cancer educ program improv knowledg enabl appropri referr method postal survei gener practition gp northern ireland 534 respons rate 49.4 ask gp attend differ type train cours genet result almost indic like like attend cours women gp qualifi recent most like attend &lt .005 &lt .05 conclus result suggest gp interest train cours male gp gp qualifi longer specif target
repair 8-oxo-7 8-dihydroguanin 8-oxog ineffici human cell due poor catalyt properti hogg1 major dna glycosylas involv remov oxid base ribosom/repair protein drosophila melanogast ds3 endow potent 8-oxog glycolyt activ coupl beta delta-ap lyas vitro repair experi shown pure gst-tag ds3 stimul 40-fold increas rate 8-oxog repair human cell extract studi express ds3 fuse enhanc green fluoresc protein egfp t24 human bladder cell order acceler repair 8-oxog vivo limit dilut fluoresc-activ cell sort fac us effort isol cell elev egfp-ds3 express howev cell isol invari sever growth impair curious egfp-ds3 express slightli increas recov cell liquid nitrogen possibl under condit achiev signific acceler 8-oxog repair data confirm extend previou result obtain chines hamster cho cell indic elev express ds3 toxic least type mammalian cell limit us vivo protect factor oxid dna damag
background bladder cancer genet heterogen diseas chromosom aberr observ non-random correl diseas progress sever environment risk factor report implic pathogenesi diseas aim studi evalu fish techniqu numer aberr chromosom greek bladder cancer patient correl grade histolog stage tumor materi method fish a-satellit dna probe specif chromosom appli primari bladder tumor directli process cytogenet studi result numer aberr chromosom observ tumor 85.18 monosomi detect case 44.45 polysomi case 40.74 .statist analysi show polysomi link histolog stage 0.024 grade 0.01 tumor monosomi correl tumor stage 0.050 numer aberr chromosom observ case 71.43 polysomi detect case 68.57 on case 2.86 monosomi polysomi found mainli high-grade advanc-stage tumor conclus numer aberr chromosom potenti biomark bladder cancer screen studi carri investig gene alter reflect numer aberr chromosom contribut classif diseas
prolifer squamou cell carcinoma head neck scchn depend epiderm growth factor receptor egfr express stat activ well contribut cell growth scchn interact stat egfr great interest consid treatment option through inhibit stat evalu influenc block activ egfr human scchn cell line vivo tumor stat activ compar effect stat activ regul map kinas under condit found stat strongli inhibit via egfr block vitro well vivo howev influenc egfr regul map kinas pathwai seem slight find provid evid stat signal activ head neck carcinoma partial respons prolif activ control via egfr
investig effect tropolon nitric oxid product mous macrophag-like raw 264.7 cell compound fail stimul raw 264 cell produc detect amount inhibit product lipopolysaccharid lp -activ raw 264.7 cell variou extent gener abil tropolon inhibit lp-stimul product invers relat cytotox activ western blot rt-pcr analys demonstr most activ compound 4-dibromo-7-methoxytropon [21] significantli reduc both intracellular concentr ino protein express ino mrna esr spectroscopi show [21] produc radic under alkalin condit nor scaveng produc noc-7 data suggest inhibitori effect [21] product gener via inhibit ino express rather radic-mediat mechan
investig effect twenti-seven azulen nitric oxid product mous macrophag-like raw 264.7 cell azulen deriv alon induc product raw 264.7 cell inhibit lipopolysaccharid lp -stimul product variou extent abil azulen inhibit gener activ macrophag gener increas cytotox activ declin western blot rt-pcr analys demonstr most potent compound 3-difluoroazulen [11] slightli inhibit express induc synthas ino extrem high concentr esr spectroscopi show [11] produc radic under alkalin condit nor scaveng o2- gener hx-xod reaction gener noc-7 data suggest inhibitori effect [11] produc via mechan ino induct radic-mediat mechan
rna helicas constitut larg group essenti enzym involv aspect rna metabol few except human rna helicas ddx dhx gene famili well character howev sever shown dysregul cancer includ over-express variou type tumor exact contribut rna helicas carcinogenesi determin over-express cancer render potenti target novel anti-cancer agent review rna helicas express up-regul cancer highlight
background antibodi calretinin repres establish power reliabl immunohistochem marker differenti diagnosi mesothelioma adenocarcinoma howev studi publish exact molecular ident immunoreact protein detect mesothelioma section yet determin materi method tissu biopsi ten mesothelioma sampl primari metastat analyz western blot analysi revers transcriptas-polymeras chain reaction rt-pcr addit immunohistochem stain result besid select posit immunoreact sampl calretinin identifi western blot analysi identif mrna rt-pcr addit identifi altern splice form calretinin-22k correspond mrna previous detect neoplast cell colon carcinoma deriv cell line conclus find demonstr immunoreact observ mesothelioma metastas investig report due concomit presenc calretinin altern splice form calretinin-22k
background multipl myeloma charecter great clinic heterogen among known prognost factor cytogenet abnorm thought major import aim studi correl certain chromosom abnorm immunoglobulin isotyp surviv patient patient method forti-nine greek patient homogen treat convent-dose chemotherapi cytogenet studi direct cultur bone marrow cell g-band techniqu result twenti-four patient normal karyotyp remain patient present numer structur abnorm recurr structur abnorm observ transloc involv 14q32 region observ case case exhibit del p12 confirm neg impact chromosom abnorm overal surviv patient show wors impact diseas outcom compar 14q32 unidentifi partner chromosom presenc del p12 significantli worsen prognosi patient correl exist associ immunoglobulin isotyp surviv certain chromosom chang conclus studi indic molecular level clarifi exact role prognost valu 1p12 involv patient
purpos studi establish subcutan model human extrahepat bile duct carcinoma nude mice provid suitabl model studi extrahepat bile duct carcinoma surgic specimen patient extrahepat bile duct carcinoma transplant subcutan layer nude mice growth curv transplant tumor drawn morpholog biolog characterist well choromosom observ well differenti mucin adenocarcinoma model human bile duct carcinoma nude mice design hbdcm1-zsh human bile duct carcinoma model establish zhong shan hospit april 2001 establish via subcutan transplant surgic resect tumor 56-year-old chines man hbdcm1-zsh maintain passag exhibit 98.1 transplant mean latent period dai transplant tumor exhibit characterist origin tumor morpholog biologi chromosom analysi reveal numer abnorm rang hbdcm1-zsh express carcinoembryon antigen cea carbohydr antigen 19-9 cytokeratin ck7 ck19 ck20 pcna pa conclus hbdcm1-zsh similar human extrahepat bile duct carcinoma provid applic anim model research extrahepat bile duct carcinoma
retinoid shown signific activ cancer prevent therapi effect mediat nuclear retinoid receptor includ retino acid receptor rar alpha beta gamma retinoid receptor rxr alpha beta gamma human retino acid receptor beta rarbeta three differ isoform beta1 beta2 beta4 tumor suppress characterist rarbeta2 silenc promot hypermethyl reexpress demethyl report contrast rarbeta1 embryon isoform restrict express adult tissu link carcinogenesi howev factor regul rarbeta1 express yet clarifi studi head neck squamou cell carcinoma cell found express rarbeta increas cell grown high densiti real-time revers-transcriptas polymeras chain reaction reveal isoform increas cell rarbeta1 epigenet modif isoform test us combin bisulfit restrict analysi chromatin immunoprecipit assai umscc38 cell line show signific rarbeta1 express &lt 0.001 depend cell densiti cultur durat increas express rarbeta1 due demethyl promot howev higher cell densiti associ increas acetyl histon lysin rarbeta1 rarbeta2 find reveal express rarbeta1 regul cell densiti through chang histon acetyl
cancer larg caus genom event activ oncogen inactiv tumor suppressor gene date mechan mutant gene product contribut tumorigenesi studi mostli experiment model system abl interrog potenti contribut development factor etiolog neoplasia recent emploi condit transgen model system demonstr abil myc oncogen induc tumorigenesi influenc development ag host myc induc embryon neonat tissu cellular prolifer rapid onset tumorigenesi wherea myc activ adult tissu induc cellular hypertrophi differ frequenc spectrum cancer observ differ ag host reflect influenc development context cancer gener better thought consequ genet event occur permiss epigenet state development context critic determin pathogenesi neoplasia
atiprimod novel compound belong azaspiran class cation amphiphil drug exhibit both anti-prolif anti-angiogen activ atiprimod inhibit prolifer human cancer cell line includ nation cancer institut panel ic50 valu low micromolar rang notabl metastat cell line sensit compound compar non-metastat cell line deriv same tumor tissu type atiprimod induc apoptosi activ both caspas-9 caspas-3 t84 colon carcinoma cell henc anti-prolif activ partli due pro-apoptot activ regard angiogenesi vitro atiprimod inhibit both bfgf vegf induc prolifer migrat human umbil vein endotheli cell huvec result disrupt cord format addit atiprimod suppress format blood vessel chorioallanto membran assai previou studi shown atiprimod treatment reduc product il-6 vegf inhibit activ stat3 constitut activ protein major human cancer togeth find suggest atiprimod act sever molecul essenti tumor growth invas metastasi
serial analysi gene express sage power tool discoveri novel tumor marker publicli avail onlin sage librari normal neoplast tissu http //www.ncbi.nlm.nih.gov/sage/ recent expand addit complet annot human genom better biocomput techniqu substanti improv assign differenti express sage tag human gene improv provid opportun re-evalu global gene express pancreat cancer us exist sage librari sage librari gener six pancreat cancer compar sage librari gener non-neoplast tissu compar normal tissu librari identifi 453 sage tag differenti express pancreat cancer includ 395 map known gene uncharacter tag 395 sage tag assign known gene 223 overexpress pancreat cancer 172 underexpress order map uncharacter differenti express sage tag gene us newli develop resourc call tagmapp http //tagmapp.ibioinformat.org identifi addit differenti express gene differenti express seven gene involv multipl cellular process signal transduct mic-1 differenti dmbt1 neugrin immun respons cd74 inflamm cxcl2 cell cycl ceb1 enzymat activ kallikrein confirm immunohistochem label tissu microarrai kallikrein cd74 dmbt1 rt-pcr ceb1 neugrin mic1 cxcl2 note neugrin on gene previous uncharacter sage tag correctli assign us tagmapp valid util program novel differenti express gene cancer type identifi revisit updat expand sage databas tagmapp prove power tool discoveri novel tumor marker through assign uncharacter sage tag
progress through cell cycl depend tempor spatial regul variou member e2f famili transcript factor two member e2f1 e2f4 oppos role cell cycl progress defin decad ago e2f1 activ cell cycl progress e2f4 function transcript repressor recent data indic transcript factor plai role cellular respons dna damag case e2f1 overexpress lead apoptosi contrast decreas express e2f4 respons sirna-mediat knockdown certain therapeut agent induc apoptosi convers increas level e2f4 confer resist apoptosi-induc therapi us clinic balanc activ two protein tumor cell great interest direct control e2f1 e2f4 action lead better diagnosi diseas improv therapeut modal
expans understand molecular basi cancer enabl appli molecular techniqu categor malign uniform inform group review describ basic molecular techniqu us purpos includ southern blot polymeras chain reaction pcr quantit pcr fluoresc situ hybrid dna microarrai proteom main applic techniqu modern manag acut leukemia chronic myeloid leukemia lymphoma breast cancer summar
diagnosi manag men evolv consider identif underli diseas mutat retproto-oncogen presymptomat detect prophylact surgic intervent accept standard care strong correl diseas phenotyp mutat genotyp alreadi allow develop mutat-guid manag strategi optim time intervent schedul follow-up manag understand depth correl increas look forward better refin manag regim fit both best care requir qualiti life need men patient
